A Study of TL-925 as a Treatment for Dry Eye Disease

Summary

In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment.

Timeline

Start

2023-02-27

Primary completion

2023-07-11

Completion

2023-07-11

Drugs

Indications